[EYEG] Eyegate Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.68 Change: -0.01 (-0.59%)
Ext. hours: Change: 0 (0%)

chart EYEG

Refresh chart

Strongest Trends Summary For EYEG

EYEG is in the medium-term down -16% below S&P in 1 month. In the long-term down -96% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities3.86 M Cash From Investing Activities-20 K Cash From Operating Activities-1.77 M Gross Profit
Net Profit-2.81 M Operating Profit-1.1 M Total Assets2.55 M Total Current Assets2.49 M
Total Current Liabilities410 K Total Debt Total Liabilities410 K Total Revenue
Technical Data
High 52 week0.69 Low 52 week0.28 Last close0.44 Last change-0.45%
RSI28.53 Average true range0.02 Beta1.12 Volume43.04 K
Simple moving average 20 days-5.03% Simple moving average 50 days-9% Simple moving average 200 days-9.69%
Performance Data
Performance Week-0.45% Performance Month-10.47% Performance Quart-17.34% Performance Half-21.08%
Performance Year-26.76% Performance Year-to-date-5.83% Volatility daily1.91% Volatility weekly4.27%
Volatility monthly8.74% Volatility yearly30.28% Relative Volume131.51% Average Volume266.9 K
New High New Low

News

2019-03-01 16:05:00 | EyeGate Pharmaceuticals Reports Full Year 2018 Financial Results and Provides Business Update

2019-01-29 06:55:00 | EyeGate Pharmaceuticals to Present at BIO CEO & Investor Conference in New York City

2019-01-16 06:55:00 | EyeGate Pharmaceuticals Announces Meeting Date with FDA

2018-11-30 12:30:00 | EYEG: Is EyeGate Eyeing FDA Filings Following Positive OBG Data in Both PRK and PE?

2018-11-21 08:45:00 | Investor Expectations to Drive Momentum within Atomera, YogaWorks, Cellect Biotechnology, Eyegate Pharmaceuticals, Zealand Pharma A/S, and Polar Power — Discovering Underlying Factors of Influence

2018-11-14 11:20:00 | Drug Sales Up, Biotech Stocks Down, Here's a Profit Opportunity

2018-11-14 06:50:00 | Today’s Research Reports on Stocks to Watch: Viking Therapeutics and EyeGate Pharmaceuticals

2018-11-13 16:05:00 | EyeGate Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

2018-11-13 09:50:00 | 4 Healthcare Stocks Investors Are Watching In November

2018-11-13 06:55:00 | EyeGate Pharma Announces Positive Results in Punctate Epitheliopathy Study

2018-11-13 06:55:00 | EyeGate Pharma Announces Positive Results in Second PRK Study

2018-10-02 06:55:00 | EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care

2018-09-28 11:45:00 | EYEG: Focus Is On OBG As U.S. Pilot Studies Fully Enrolled. Data Expected Q4. EGP-437 Ph3 AE Data Disappoints

2018-09-25 06:55:00 | EyeGate Pharmaceuticals Granted Additional 180 Days to Comply With Nasdaq Listing Rules

2018-09-24 06:55:00 | EyeGate Pharmaceuticals Completes Enrollment in Both PRK and PE Pilot Studies

2018-09-04 08:31:00 | EyeGate Announces Randomization of First Patients in Study for Punctate Epitheliopathies

2018-09-04 08:30:00 | EyeGate Announces Top-Line Results for Phase 3 Trial of EGP-437 in Anterior Uveitis

2018-08-29 08:30:00 | EyeGate Pharmaceuticals Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference

2018-08-20 08:30:00 | EyeGate Announces Enrollment of First Patient in PRK Pilot Study

2018-08-07 08:30:00 | EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf

2018-08-03 08:30:00 | EyeGate Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

2018-07-26 09:30:00 | EYEG: IDEs Approved. Both OBG Clinical Studies Set to Kick-Off

2018-07-25 08:06:01 | EyeGate Pharmaceuticals Stock Rose ~5.8% on July 24

2018-07-24 08:30:00 | EyeGate Announces FDA Approval of Two IDE Submissions for Ocular Bandage Gel

2018-07-10 07:45:00 | Free Pre-Market Technical Pulse on FibroGen and Three More Biotech Stocks

2018-06-22 08:30:00 | EyeGate Addresses Final FDA Action Item with Submission of IDE Amendment for Ocular Bandage Gel

2018-06-11 07:00:00 | Blog Exposure - FibroGen Completed Enrollment in US Phase-3 Clinical Program for Roxadustat in CKD Associated Anemia

2018-05-30 08:30:00 | EyeGate Files Supplement to Investigational Device Exemption to Commence Study in Punctate Epitheliopathy using the EyeGate Ocular Bandage Gel

2018-05-29 10:35:00 | EYEG: 3 of 4 FDA Questions Answered, OBG-PRK Study On-Track for Q3 Start

2018-05-25 21:37:45 | Want To Invest In EyeGate Pharmaceuticals Inc NASDAQ:EYEG? Here’s How It Performed Lately

2018-05-22 08:30:00 | EyeGate Addresses Majority of FDA’s Action Items with Submission of Investigational Device Exemption Amendment for Ocular Bandage Gel

2018-05-16 16:30:00 | EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd

2018-05-11 08:30:00 | EyeGate Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update

2018-05-07 08:11:19 | Are Insiders Too Confident In EyeGate Pharmaceuticals Inc NASDAQ:EYEG?

2018-04-17 16:30:00 | EyeGate Announces Completion of $11.25 Million Public Offering

2018-04-13 07:00:00 | EyeGate Announces $11.25 Million Public Offering

2018-04-11 08:30:00 | EyeGate Issued New Patent for Iontophoretic Contact Lens Technology

2018-04-09 08:30:00 | EyeGate Receives FDA Feedback on Investigational Device Exemption Amendment for Second Pilot Study of Ocular Bandage Gel

2018-04-06 08:30:00 | EyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 in Anterior Uveitis

2018-03-09 08:30:00 | EyeGate Pharma To Participate At The 30TH Annual ROTH Conference

2018-03-08 15:31:31 | EyeGate Pharmaceuticals Inc NASDAQ:EYEG: Poised For Long-Term Success?

2018-03-08 08:30:00 | EyeGate Pharma Submits Investigational Device Exemption Amendment for Second Pilot Study of Ocular Bandage Gel

2018-03-02 16:28:12 | EyeGate Pharmaceuticals Reports Full-Year 2017 Financial Results and Provides Business Update

2018-02-21 11:30:00 | EYEG: Cataract Surgery Phase II Topline Data: Efficacy Signal Despite Miss to Primary Endpoint

2018-02-07 08:30:00 | EyeGate to Present at the 2018 BIO CEO & Investor Conference

2018-02-05 10:20:42 | What Spooked Eyegate Pharmaceuticals Inc Investors Today

2018-02-05 08:30:00 | EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery

2018-01-19 18:55:23 | Should You Worry About Eyegate Pharmaceuticals Inc’s NASDAQ:EYEG CEO Pay Check?

2018-01-04 08:30:00 | EyeGate Promotes Sarah Romano to Chief Financial Officer

2018-01-02 15:19:10 | With A -14.24% Earnings Drop Lately, Did Eyegate Pharmaceuticals Inc NASDAQ:EYEG Underperform Its Industry?